A Study of MR-Guided Focused Ultrasound for the Treatment of Low- and Intermediate-Stage Prostate Cancer

Full Title

Focal MR-Guided Focused Ultrasound Treatment of Localized Low and Intermediate Risk Prostate Cancer: Feasibility Study

Purpose

The purpose of this study is to assess the safety and feasibility of a novel focal therapy in men with prostate cancer that is confined to the prostate. The therapy is called magnetic resonance (MR)-guided focused ultrasound. High-energy sound waves are targeted to prostate cancer cells, heating them and killing them. The goal of the therapy is to treat only the areas with prostate cancer cells and preserve the remaining prostate gland. Researchers will also see if the treatment is associated with less side effects, such as incontinence (problems controlling urination) or impotence (erectile dysfunction), compared to conventional therapies.

The MR-guided focused ultrasound being evaluated in this study is already approved for treating uterine fibroids and cancer that has spread to the bones, but its use in prostate cancer is considered investigational.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have prostate cancer that is confined to the prostate and has not been previously treated.
  • Patients must be able to undergo MRI.
  • This study is for men ages 55 to 75.

For more information and to inquire about eligibility, please contact the principal investigator for this study, Dr. Behfar Ehdaie, at (646) 422-4406.

Protocol

14-007

Phase

I

Investigator

Co-Investigators

Locations